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ABSTRACT 5 
Background: Health-related quality of life (HRQL) is a global indicator of perceived 6 
health status, which includes physical and mental domains. Several biological 7 
mechanisms might support an association between consumption of yogurt and better 8 
HRQL.  9 
Objective: To assess the association between habitual yogurt consumption and HRQL 10 
in the general adult population. 11 
Design: Prospective study with 4445 individuals aged ≥18 years who were recruited in 12 
2008-2010 and followed-up to 2012. Habitual yogurt consumption was assessed at 13 
baseline with a validated diet history. HRQL was measured with the physical composite 14 
summary (PCS) and the mental composite summary (MCS) of the Spanish version of 15 
the SF-12 questionnaire. The analysis of the association between baseline yogurt 16 
consumption and HRQL at 2012 was performed with linear regression and adjusted for 17 
the main confounders, including baseline HRQL.  18 
Results: The mean follow-up was 3.5 (standard deviation: 0.6) years. Compared to non-19 
consumers of yogurt, the PCS scores were similar in habitual consumers of ≤ 6 20 
servings/week (beta: 0.40; p value= 0.20) and in consumers of ≥1 serving/day (beta: 21 
0.25; p value= 0.45). A suggestion of tendency towards a lower MCS score was found 22 
among daily yogurt consumers (beta: -0.65, p value= 0.09; p for trend across 23 
categories= 0.07). The results were similar among individuals without morbidity, never 24 
smokers and persons with higher adherence to the Mediterranean diet.   25 
Conclusion: Habitual yogurt consumption did not show an association with improved 26 
HRQL.   27 
28 
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INTRODUCTION 29 
Health-related quality of life (HRQL) is a global indicator of perceived health status, 30 
which includes physical and mental domains. Poor HRQL has been associated with 31 
greater use of health-care services1,2 and with higher short- and long-term mortality, 32 
particularly among older adults.3  33 
The main dietary guidelines in Spain and other countries support the consumption of 34 
dairy products as part of a healthy diet.4,5 Because most studies have focused on the 35 
effect of total dairy, it is interesting to assess the independent association between each 36 
type of dairy and global indicators of health, such as HRQL. Several biological 37 
mechanisms suggest that there is pathway whereby yogurt consumption may influence, 38 
directly or indirectly, the HRQL. Specifically, yogurt consumption has been associated 39 
with lower weight gain,6,7 which in turn may lead to improved HRQL.8 Moreover, the 40 
consumption of dairy products has been linked to lower blood pressure,9,10 and 41 
hypertension awareness and treatment are related to impaired HRQL.11 Also, yogurt is 42 
rich in calcium, which is bone protective, and it is known that osteomuscular disease is 43 
one of the health disorders with the greatest negative impact on HRQL.12 In addition, it 44 
has been suggested that probiotics found in yogurt may improve gastrointestinal 45 
disorders13 and also affect activity of brain regions that control central processing of 46 
emotion and sensation.14 Lastly, in specific patient samples, there is some evidence that 47 
administration of probiotics reduced lower gastrointestinal symptoms and led to 48 
improvement in quality of life.15,16 49 
Assessing the association between individual foods and HRQL is important because 50 
both the food industry and the population as a whole are interested in knowing whether 51 
general well-being could be improved by consuming specific foods. To our knowledge, 52 
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however, the effect of yogurt on HRQL has not yet been studied in epidemiological 53 
investigations in the general population. Thus, the objective of this article was to 54 
examine the prospective association between habitual yogurt consumption and the 55 
physical and mental components of HRQL among the general adult population. 56 
57 
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METHODS 58 
Study design and participants 59 
Data were taken from a cohort of 6,207 Caucasian individuals aged 18 years and older. 60 
Cohort members were selected through random sampling of participants in the ENRICA 61 
study17 with over-representation of older adults. Baseline information was obtained in 62 
2008-2010 in three stages: a phone interview to collect information on health status, 63 
lifestyle, morbidity and health services use; a first home visit to obtain samples of blood 64 
and urine; and a second home visit to perform a physical examination and to record 65 
habitual diet. In 2012, a phone interview was conducted to update information on 66 
lifestyles other than diet, HRQL and morbidity in a subsample of 4,887 (78.7%) 67 
participants. All interviewers at baseline and at follow-up received specific training in 68 
the study procedures. 69 
Study participants gave informed written consent. The Clinical Research Ethics 70 
Committee of the ‘La Paz’ University Hospital in Madrid approved both the baseline 71 
and follow-up studies. 72 
Yogurt consumption 73 
Habitual food consumption in the previous year was assessed at baseline with a 74 
validated computerized diet history, developed from the one used in the EPIC-Spain 75 
cohort study.18,19 Yogurt consumption (including fermented milk) was recorded in detail 76 
by asking the participants whether they consumed whole milk or reduced-fat type. We 77 
considered that the average serving of yogurt was 125 g and defined the following three 78 
categories of consumption: no consumption, 1-3 servings/month up to 6 servings/week, 79 
and ≥1 serving/day. In addition, calcium, sugar, and saturated fat (important nutrients in 80 
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yogurt) and total energy intake were estimated using standard food composition 81 
tables.20,21 82 
Health-related quality of life  83 
HRQL represents the individual perception of the impact of a disease or a risk factor 84 
(e.g., yogurt consumption) on different spheres of life, including physical, mental and 85 
social aspects. HRQL was measured at baseline and at the end of follow-up using the 86 
SF-12 v.2 questionnaire, which has been validated in Spain.22 This is a reduced version 87 
of the SF-36 questionnaire, one of the most widely used instruments to evaluate HRQL. 88 
This shorter version was obtained by selecting 12 items whose responses are coded and 89 
analyzed to reproduce the physical composite summary (PCS) and the mental composite 90 
summary (MCS) from the longer version. The PCS and MCS scores are standardized to 91 
a national norm with a mean of 50.0 and a standard deviation of 10.0. A zero score in 92 
PCS or MCS indicates the lowest level of health, and a score of 100 indicates the 93 
highest level.  94 
Despite being a short version of the SF-36 questionnaire, the SF-12 has excellent 95 
criterion validity because it explained over 90% of the variability in the PCS and MCS 96 
scores on the SF-36. The SF-12 has also shown good reliability for group 97 
comparisons.22  98 
Potential confounders of the study association 99 
Study participants reported their age, educational level, smoking habit, and the total 100 
amount of hours of sleep per day. Information on physical activity during leisure time 101 
was obtained with the questionnaire developed for the EPIC-Spain cohort, and was 102 
expressed in METs h/week.23 The above information was obtained at baseline and 103 
updated at the end of the follow-up.  104 
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Accordance with the Mediterranean diet was evaluated at baseline with the 105 
Mediterranean Diet Adherence Screener (MEDAS).24 The MEDAS consists of 12 items 106 
with targets for food consumption and another 2 items with targets for food intake 107 
habits characteristic of the Mediterranean diet in Spain. One point is given for each 108 
target achieved. The scale ranges from 0 to 13 (without including alcohol consumption, 109 
which was considered an independent potential confounder). We considered that a 110 
MEDAS score ≥6 represented moderate accordance. 111 
Baseline weight and height were measured in each subject under standardized 112 
conditions. Body mass index (BMI) was calculated as weight in kg divided by squared 113 
height in m. Blood pressure (BP) was determined with a validated sphygmomanometer, 114 
and  glucose and cholesterol levels were measured in serum samples, using standard 115 
protocols at baseline.25-27 Hypertension was defined as systolic BP ≥140 mm Hg, 116 
diastolic BP ≥90 mm Hg, or being under antihypertensive drug treatment. Type 2 117 
diabetes was defined as fasting serum glucose ≥126 mg/dl or being treated with oral 118 
drugs or insulin, and hypercholesterolemia as serum total cholesterol ≥200 mg/dl or 119 
receiving lipid-lowering drugs. Finally, participants also reported if in the year prior to 120 
the baseline and follow-up interviews they had suffered any of the following physician-121 
diagnosed diseases: asthma or chronic bronchitis, cardiovascular disease, sleep apnea, 122 
osteoarthritis, rheumatoid arthritis, hip fracture, gallstones, intestinal polyps, cirrhosis of 123 
the liver, peptic ulcer, cataracts, cancer at any site, Parkinson disease, and Alzheimer 124 
disease. 125 
Statistical analysis 126 
Of the individuals followed up to 2012, 4780 were alive at the time of the interview. Of 127 
these, 4445 provided complete information on the study variables and formed the 128 
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analytical sample. Individuals excluded from the analyses were less educated, 129 
performed less leisure-time physical activity and had higher BMI; they also showed a 130 
higher prevalence of hypertension, diabetes, hypercholesterolemia and other chronic 131 
diseases. 132 
Differences in baseline characteristics and changes from baseline to the end of follow-133 
up across yogurt consumption categories were examined with the use of analysis of 134 
variance and the chi-square test. We used linear regression to examine the association 135 
between baseline yogurt consumption and the SF-12 summaries in 2012; the main 136 
results were expressed as beta coefficients for the SF-12 summaries across categories of 137 
yogurt consumption. The analyses were adjusted for baseline HRQL, age, sex, 138 
education, change in smoking status, baseline and change in physical activity and sleep 139 
duration, the baseline MEDAS score and alcohol intake, and for BMI, hypertension, 140 
diabetes, hypercholesterolemia, and reported prevalent and incident chronic diseases. 141 
We also studied whether adjustment for important nutrients (in tertiles) in yogurt could 142 
modify the results. All variables were modeled as categorical by using dummy terms, 143 
except baseline HRQL which was modeled as a continuous variable. To test for linear 144 
trends across categories, we modeled yogurt consumption as a continuous variable in 145 
the models with the median value of each level of yogurt consumption. 146 
Finally, to assess the robustness of the results, we conducted stratified analyses by 147 
categories of disease status, smoking status, and accordance with the Mediterranean 148 
diet. To examine whether the results varied between strata we used the Wald test for the 149 
interaction term, defined as the product of yogurt consumption by each stratification 150 
variable.  151 
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Given that we found no sex interactions (p=0.88 for the PCS and 0.81 for the MCS), our 152 
results are presented for the total study sample. Statistical significance was set at 2 153 
tailed p <0.05. The analyses were performed with SAS (version 9.2, SAS Institute Inc., 154 
Cary, NC) statistical software.155 
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RESULTS 156 
Among study participants, 65% were yogurt consumers. The reported mean and 157 
standard deviation (SD) of yogurt consumption were 0.58 (0.64) servings/day; of this 158 
amount, 0.27 (0.50) servings/day corresponded to whole-milk yogurt and 0.30 (0.53) 159 
servings/day to reduced-fat yogurt. The characteristics of the study population by 160 
categories of yogurt consumption are shown in Table 1. Compared to non-consumers of 161 
yogurt, those with the highest consumption were mostly women, with lower education 162 
level; they were also less likely to smoke and drank less alcohol. Calcium and sugar 163 
intake were higher among participants in the highest category of consumption, but 164 
saturated fat and total energy intake were similar in all three categories. Lastly, the 165 
prevalence of hypertension and osteomuscular disease was higher among yogurt 166 
consumers at baseline and in 2012.  167 
The mean (SD) follow-up was 3.5 (0.6) years. Multivariable linear regression models 168 
showed that compared to non-consumers of yogurt, the PCS scores at follow-up were 169 
similar in consumers of ≤ 6 servings/week (beta: 0.40, p value= 0.20) and in consumers 170 
of ≥ 1serving/day (beta: 0.25, p value= 0.45) (Table 2). A tendency towards a lower 171 
MCS at follow-up was found among daily yogurt consumers (beta: -0.65, p value= 0.09; 172 
p for trend across categories of consumption= 0.07) (Table 2). These results held after 173 
additional adjustment for calcium, saturated fat and sugar intake, and for total energy 174 
intake. When the analysis was disaggregated by type of yogurt, the consumption of 175 
reduced-fat yogurt seemed to account for the inverse association observed with MCS 176 
(beta: -0.95, p=0.02) (Table 2).  177 
We also stratified the analyses by categories of disease status, smoking consumption 178 
and adherence to the Mediterranean diet. No association between yogurt consumption 179 
11 
 
and the PCS or MCS scores was found in any of the stratification variables (Table 3).180 
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DISCUSSION 181 
In this study, we found no association between yogurt consumption and the physical 182 
and mental components of HRQL after 3.5 years of follow-up of a population-based 183 
cohort. The results also held for whole-milk and reduced-fat yogurt. According to the 184 
European Food Safety Authority (No. 1924/2006), health claims in food products must 185 
be scientifically evaluated. In addition, the U.S. Department of Agriculture revises 186 
health claims proposed by the food industry in light of the current scientific evidence to 187 
allow or reject the use of those claims for marketing purposes.28 Therefore, our results 188 
add a new piece of information to evaluate health claims from the dairy industry.  189 
Given that yogurt is a nutrient-dense milk product, most research in nutritional 190 
epidemiology has included this food within a large category of dairy products. Thus, 191 
few studies have specifically examined the effect of yogurt consumption on health. 192 
Mozaffarian et al.,6 using two large cohort studies, found that an increase in the intake 193 
of yogurt (1 serving/day) was associated with losing 0.82 lb. over a 4-year period. Also, 194 
Wang et al.7 have recently reported that individuals with a habitual intake of 3 195 
servings/week had a smaller annual weight gain (-0.10 ±0.04 kg) than those consuming 196 
<1 serving/week. Moreover, yogurt consumption has been associated with better diet 197 
quality.29 Lastly, in a meta-analysis of 5 cohort studies,9 the consumption of yogurt and 198 
milk for the highest versus the lowest intake category was associated with a reduced 199 
risk of hypertension (relative risk: 0.92, 95% CI: 0.87-0.98); however, a more recent 200 
meta-analysis10 including 9 cohort studies found a null association (relative risk: 0.99; 201 
95% CI: 0.96-1.01, per 50 g/day of yogurt).  202 
Although the available evidence suggests an inverse association between total dairy 203 
consumption and cardiovascular disease,30 no specific effect of yogurt on cardiovascular 204 
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endpoints has been found.31,32 Similarly, the inverse association found between total 205 
dairy products and risk of type 2 diabetes33 has not been observed consistently for 206 
yogurt.34,35 Finally, yogurt consumption has been associated with other health outcomes, 207 
including lower risk of colorectal cancer,36 reduced anxiety and depression,37 and 208 
greater lean body mass and better physical performance.38 209 
Potential health effects of yogurt can be related to its nutrient content, including 210 
saturated fat, protein, sugar and calcium, as well as probiotics. Whole-milk yogurt is an 211 
important source of saturated fat in the diet, and higher consumption of high-fat dairy 212 
products has been linked to increased risk of coronary heart disease.39 However, another 213 
study found that high consumption of yogurt was not associated with increased risk of 214 
all-cause or cardiovascular mortality, in contrast with other foods rich in saturated fat.40 215 
In our study, no differences were found between whole-milk and reduced-fat yogurt; 216 
however, this should not be taken as an indication that saturated fat does not exert a 217 
negative effect on HRQL, because in our study fat from yogurt represented only a tiny 218 
fraction of all saturated fat in the diet.41 Moreover, yogurt has been identified as one of 219 
the foods that most contributed to added sugar intake in the diet of the hypertensive and 220 
diabetic individuals in our cohort.41 We were unable to evaluate separately sugary and 221 
non-sugary yogurt, but most of the yogurt consumed in this cohort was sugar-222 
sweetened, thus any yogurt-related health claim should account for the detrimental 223 
health effects of added sugars.42   224 
There is consistent evidence of a key role of calcium and vitamin D in skeletal health. 225 
Results from meta-analyses of clinical trials43,44 and large prospective studies45 suggest 226 
that low levels of calcium are associated with higher risk of bone fractures, although it 227 
seems that this effect has a threshold because an increased intake does not reduce 228 
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fracture risk. None of the above studies examined the effect of each specific source of 229 
calcium intake. Nevertheless, a recent prospective study investigated the association 230 
between types of dairy products and bone mineral density and hip fracture risk over 12 231 
years of follow-up;46 yogurt was the only dairy product that showed a marginally 232 
protective effect on fracture risk. On the other hand, high levels of total calcium intake 233 
have been associated with increased all-cause and cardiovascular mortality in some47 234 
but not all studies.483 Thus, recommendations to increase dairy consumption based on 235 
their calcium contribution to the diet should be made with caution.  236 
Yogurt also provides potassium and B vitamins, in particular vitamins B1 and B2. There 237 
is some evidence of the association between potassium intake and blood pressure 238 
reduction in adults, which in turn influences the risk of stroke and coronary heart 239 
disease.49 Evidence is also accumulating of the protective effect of adequate dietary 240 
potassium on age-related bone loss and reduction of kidney stones.49 As regards 241 
vitamins B1 and B2, they may be effective in cataract prevention.50  242 
Finally, it has been suggested that probiotics contained in yogurt are able to reduce 243 
mucosal inflammation of the digestive tract and alterations in gut microflora.51 In fact, 244 
some clinical trials support the effect of fermented milks in reducing digestive 245 
symptoms in patients with irritable bowel syndrome.52 However, the evidence is still 246 
weak because, in a review of the literature on this topic, 11 of the 16 clinical trials 247 
included had a suboptimal design.13 In addition, it is not yet clear if yogurt consumption 248 
improves gastrointestinal transit time.53 249 
Given the variety of potential effects of yogurt consumption described above, which 250 
affect the cardiovascular, digestive, central nervous and osteomuscular systems, it 251 
would be reasonable to expect an association between yogurt and HRQL, because the 252 
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latter represents a global health indicator. However, the evidence on several effects of 253 
yogurt is still preliminary, because for some disorders it is not fully consistent (e.g., 254 
reduced risk of diabetes mellitus) or does not have a high quality (e.g., improved 255 
symptoms in irritable bowel syndrome). Also, in some cases the magnitude of the effect 256 
does not seem to be strong (e.g., reduced weight gain) and in another cases the potential 257 
effect is asymptomatic (e.g. on blood pressure), thus it may not translate into better 258 
health perception. Therefore, the available organ/system-specific evidence is 259 
insufficient either to ensure a benefit of yogurt on HRQL or to entirely rule it out.  260 
Among the strengths of this study was that yogurt consumption was ascertained using a 261 
validated diet history that distinguished between whole-milk and reduced-fat varieties. 262 
Another strength was the relatively large sample size, which allowed performance of 263 
stratified analyses. Lastly, the analyses were adjusted for a number of well measured 264 
potential confounders including accordance with the Mediterranean diet.   265 
Among the limitations is the assumption that yogurt intake was stable over the follow-266 
up, which may underestimate the study associations; however, the effect estimates were 267 
very small and, in particular, fell far short of achieving clinical relevance (e.g., a change 268 
in ≥3 points in PCS or MCS)20 so it is unlikely that this limitation can fully explain the 269 
lack of association between yogurt and HRQL. Also, yogurt consumption was relatively 270 
low even in the highest category, which precluded assessment of the impact of high 271 
amounts of yogurt on HRQL. Of note is that mean yogurt consumption in our cohort 272 
was somewhat higher than in the national study of food consumption conducted in 2008 273 
(0.58 servings/day vs. 0.38).54 Moreover, the relatively short follow-up may not have 274 
sufficed to accrue some potential benefits of yogurt, such as reduced fractures; thus, our 275 
results should be confirmed in prospective studies with longer duration. Lastly, HRQL 276 
has been obtained by self-report. Moreover, the SF-12 does not include sleep quality or 277 
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cognitive function. Thus, future research should examine the influence of yogurt on 278 
these important health dimensions. Also, the SF-12 questionnaire is a generic tool to 279 
assess HRQL and may not capture the potential benefits of yogurt on specific domains, 280 
such as digestive or bone health.  281 
In conclusion, habitual yogurt consumption did not show an association with improved 282 
HRQL in a Caucasian population. Future population-based research should use disease-283 
specific instruments to assess HRQL, in addition to generic instruments, because it may 284 
increase the likelihood of finding a potential benefit of yogurt on HRQL.  285 
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Table 1. Age-adjusted characteristics of study participants according to categories of total yogurt consumption. N=4445 
 
 Total yogurt consumption, servings  
 Never 1-3 per month up 
to 6/week 
≥1 per day P 
valuea 
Participants, n 1549 1607 1289  
At baseline     
 Age, y 55 (17) 53 (17) 56 (17)  
 Men, % 56.7 47.0 42.3 <0.001 
 Education, primary or less, % 37.9 33.6 38.9 0.009 
 Sleep, hours/day 7.3 (0.03) 7.3 (0.03) 7.2 (0.04) 0.15 
 Leisure-time physical activity, METs-h/week 26.9 (0.5) 25.8 (0.5) 26.9 (0.5) 0.95 
 MEDAS scoreb 6.5 (0.04) 6.3 (0.04) 6.8 (0.05) <0.001 
 Alcohol intake, g/day 14.5 (0.5) 11.4 (0.5) 10.6 (0.5) <0.001 
 Calcium, mg/day 799 (8) 883 (8) 991 (9) <0.001 
 Sugar, g/day 87 (0.9) 94 (0.9) 100 (1.0) <0.001 
 Saturated fat, g/day 27 (0.3) 28 (0.3) 27 (0.3) 0.32 
 Total energy, kcal/day  2167 (15) 2197 (15) 2135 (17) 0.18 
 BMI, kg/m2 27.3 (0.1) 27.3 (0.1) 27.5 (0.1) 0.26 
 Hypertension, % 44.9 39.7 47.6 <0.001 
 Diabetes, % 9.9 8.5 9.5 0.38 
 Hypercholesterolemia, % 58.9 57.7 60.3 0.37 
 Osteomuscular diseasec, % 28.2 28.9 34.5 <0.001 
 Other chronic diseasesd,% 35.0 33.4 36.7 0.21 
 PCS 49.1 (0.3) 49.1 (0.2) 48.4 (0.3) 0.07 
 MCS 51.2 (0.2) 51.1 (0.2) 51.1 (0.3) 0.74 
Changes from baseline to the end of follow-up     
 Smoker at baseline and at end of follow-up, % 51.4 47.2 39.1 <0.001 
 Not smoker at baseline but smoker at end of follow-up, % 3.5 3.9 4.7 <0.001 
 Smoker at baseline but not smoker at end of follow-up, % 4.7 4.3 4.4 <0.001 
 Change in sleeping time, hours/day -0.3 (0.03) -0.2 (0.03) -0.2 (0.04) 0.34 
 Change in leisure time physical activity, METs-h/week 0.5 (0.5) 0.7 (0.5) -0.3 (0.6) 0.27 
 Incident osteomuscular disease, % 29.9 31.0 34.2 0.04 
 Other incident chronic diseases, % 37.2 37.0 40.4 0.63 
 Change in PCS -0.99 (0.2) -0.77 (0.2) -0.61 (0.3) 0.32 
 Change in MCS 0.61 (0.3) 0.68 (0.02) -0.32 (0.3) 0.04 
For continuous variables, reported values are mean (SE). 
PCS: physical summary; MCS: mental summary. 
aObtained from ANOVA for continuous variables and from chi-square test for categorical variables. 
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bMediterranean Diet Adherence Screener.  
cIncluding osteoarthritis, rheumatoid arthritis, and hip fractures. 
dIncluding asthma or chronic bronchitis, cardiovascular disease, sleep apnea, gallstones, intestinal polyps, cirrhosis of the liver, peptic ulcer, cataracts, cancer at any site, Parkinson disease, and 
Alzheimer disease. 
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Table 2. Beta coefficients (p value) for the association between categories of baseline yogurt consumption and follow-up SF-12 health questionnaire 
summaries.  
 Consumption, servings 
 Never 1-3 per month up to 
6/week 
≥1 per day P for trend 
Total yogurt     
 Participants, n 1549 1607 1289  
 Median consumption, s/d 0 0.50 1.0  
 PCS    
 Age and sex-adjusted model Ref. 0.44 (0.25)  0.02 (0.96) 0.95 
 Multivariable modela Ref. 0.40 (0.20) 0.25 (0.45) 0.50 
 Multivariable modelb Ref. 0.32 (0.32) 0.09 (0.80) 0.85 
 MCS    
 Age and sex-adjusted model Ref. 0.31 (0.43) -0.53 (0.19) 0.20 
 Multivariable modela Ref. 0.19 (0.59) -0.65 (0.09) 0.07 
 Multivariable modelb Ref. 0.19 (0.61) -0.69 (0.09) 0.07 
Whole-milk yogurt     
 Participants, n 2877 998 570  
 PCS    
 Age and sex-adjusted model Ref. 0.30 (0.45) -0.18 (0.71) 0.93 
 Multivariable modela Ref. 0.26 (0.42) -0.24 (0.55) 0.70 
 MCS    
  Age and sex-adjusted model Ref. -0.04 (0.91) -0.12 (0.81) 0.81 
 Multivariable modela Ref. -0.04 (0.92) -0.24 (0.60) 0.56 
Reduced-fat yogurt     
 Participants, n 2910 846 689  
 PCS     
 Age and sex-adjusted model Ref. 0.18 (0.67) -0.24 (0.60) 0.75 
 Multivariable modela Ref. 0.23 (0.50) 0.21 (0.58) 0.49 
 MCS    
 Age and sex-adjusted model Ref. 0.45 (0.29) -1.01 (0.03) 0.12 
 Multivariable modela Ref. 0.29 (0.46) -0.95 (0.03) 0.09 
PCS: physical summary; MCS: mental summary. 
aLinear regression model adjusted for age (18-44, 45-64 y), sex, SF-12 summary scores at baseline (continuous), educational level (primary or less, secondary, university), alcohol intake in 
2008-10 (tertiles of g/d), Mediterranean Diet Adherence Screener in 2008 (<6, ≥6), change in smoking status (never smoker, smoker in 2008-10 and 2012, not smoker in 2008-10 but smoker in 
2012, and smoker in 2008-10 but not smoker in 2012), baseline and change in physical activity during leisure time and sleep duration (tertiles), BMI in 2008-10 (<25, 25-<30, ≥30 kg/m2), and 
hypertension, hypercholesterolemia, diabetes and chronic diseases in 2008-10 and in 2012. 
bLinear regression model with additional adjustment for calcium, saturated fat, sugar and total energy intake (in tertiles). 
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Table 3. Beta coefficients (p value) for the association between categories of baseline yogurt consumption and follow-up SF-12 health questionnaire 
summaries, stratified by diagnosed diseases, smoking, and the Mediterranean Diet Adherence Screener (MEDAS)a 
 Total yogurt consumption, servings  
 Never 1-3/month up to 
6/week 
≥1 per day P for 
trend 
P for 
interactionb 
PCS      
  Diagnosed diseasesc     
 No (n=1853) Ref. 0.18 (0.50) 0.48 (0.21) 0.22 
0.85 
 Yes (n=2592) Ref. 0.23 (0.64) -0.06 (0.90) 0.90 
  Smoking status     
 Never (n=2011) Ref. 0.30  (0.54) 0.04 (0.93) 0.96 
0.07 
 Past and current (n=2434) Ref. 0.51 (0.21) 0.43 (0.34) 0.31 
  MEDAS     
 ≥6 (n=3217) Ref. 0.34 (0.36) 0.17 (0.66) 0.66 
0.20 
 <6 (n=1228) Ref. 0.55 (0.86) 0.12 (0.86) 0.81 
MCS      
  Diagnosed diseases     
 No Ref. -0.09 (0.85) -0.59 (0.26) 0.27 
0.66 
 Yes Ref. 0.41 (0.43) -0.70 (0.19) 0.20 
  Smoking status     
 Never Ref. -0.46 (0.41) -0.78 (0.17) 0.17 
0.69 
 Past and current Ref. 0.64 (0.17) -0.81 (0.12) 0.16 
  MEDAS     
 ≥6 Ref. 0.15 (0.72) -0.61 (0.16) 0.16 
0.35 
 <6 Ref. 0.17 (0.80) -0.99 (0.20) 0.23 
PCS: physical summary; MCS: mental summary. 
aAdjusted for age (18-44, 45-64 y), sex, SF-12 summary scores at baseline (continuous), educational level (primary or less, secondary, university), alcohol intake in 2008-10 (tertiles of g/d), 
Mediterranean Diet Adherence Screener in 2008-10 (<6, ≥6), change in smoking status (never smoker, smoker in 2008-10 and 2012, not smoker in 2008-10 but smoker in 2012, and smoker in 
2008-10 but not smoker in 2012), baseline and change in physical activity during leisure time and sleep duration (tertiles), BMI in 2008-10 (<25, 25-<30, ≥30 kg/m2), and hypertension, 
hypercholesterolemia, diabetes and chronic diseases in 2008-10 and  in 2012, except for the stratification variable in each model. 
 bp value from the Wald test calculated for the estimate of the interaction term between yogurt consumption and each stratification variable. 
cIncluding obesity, hypertension, hypercholesterolemia, diabetes, osteomuscular disease and other chronic diseases. 
 
 
